Live Deals
Active Portfolio
Revolutionizing the way the world views science
Seed
Series A
Pre-B Bridge
Series A
Pre-B Bridge
- $8.2 billion global market opportunity
- Award-winning products with $22 million in sales
- New products in R&D for advanced applications
Offered By: Bioverge Funds Management LLC
Removal of Toxic Protein Buildup to Treat ALS/Neurodegenerative Diseases
Seed
Series A
Series A
- Potential to Slow/Halt Progression of ALS
- Funding & Strategic Support from Amgen, Thiel,...
- World-Class Team (Harvard, MIT, Medtronic, J&J,..)
Offered By: Bioverge Funds Management LLC
Personalized microbiome health services & data platform
Seed
- Focus on clinical-grade data and quality control
- $1M+ revenue, 15% monthly growth, 55% retention
- Partnering with major Pharma/food/chem companies
Offered By: Bioverge Funds Management LLC
Changing the way cancer is treated
Seed
Series A
Pre-B
Series B
Series A
Pre-B
Series B
- Platform identifies personalized drug combinations
- Highly accurate drug response predictions
- Multiple academic/pharma partnerships underway
Offered By: Bioverge Funds Management LLC
Wireless Electronics to Stimulate Surgical Healing of Bone
Seed
- Stimulate/Adjust/Monitor Bone Growth in Real Time
- Tackling an Annual $80B Problem in Orthopedics
- SmartFuse: Heals Bone 4X Better, 2X Faster, Safer
Offered By: Bioverge Funds Management LLC
AI-driven, personalized nutrition platform
Seed
- Curated, adaptive, on-demand meal guidance
- 6 Acquisition offers; Partnership with Apple
- $300B+ ‘Food as Medicine’ market
Offered By: Bioverge Funds Management LLC
Helping global populations live chronic disease-free
Seed
- Digital diabetes prevention 2X effective as drugs
- Reducing risk of Type-2 Diabetes by 60%
- International partnership with Merck KGaA
Offered By: Bioverge Funds Management LLC
Crowdsourcing medical expertise
Seed
- Solving elusive cases (avg: 6+ years, 8+ doctors)
- 1M+ unique monthly visitors
- 5-18X ROI for doctors/health plans/employers
Offered By: Bioverge Funds Management LLC
Early Diagnosis and Treatment of Alzheimer's Without Drugs
Seed
- 250M Alzheimer's Patients thru 2050 = $5.4T Market
- AD Drugs Failing in Humans; Only Treating Symptoms
- Predict AD Risk, Prevent & Treat Underlying Cause
Offered By: Bioverge Funds Management LLC
AI-Powered Drug Discovery for Neurodegenerative Diseases
Seed
- Leading edge biology combined w/ machine learning
- Female Founder & CEO leads top-tier team
- World-class research partnerships
Offered By: Bioverge Funds Management LLC
BV Showcase
Revolutionizing preclinical drug discovery research
- 50% cost reductions, 70% efficiency improvements
- Tier 1 paid clients: Novartis, Denali, Jackson Lab
- Vetted, Awarded $1.85M in funding from NIH
Offered By: Bioverge Inc
Next-generation 3D bioprinting platform
- Proprietary, light-based 3D bioprinting
- 10x Speed and 5x Resolution
- Most advanced engineered tissue ever
Offered By: Bioverge Inc
Mining the microbiome for novel therapeutic molecules
- Computational drug discovery from within the body
- Vast Data Engine: 10k patient samples, 38TB data
- 2 Paid industry clients, 7 partner clinical orgs
Offered By: Bioverge Inc
The Bioverge platform is host to both Regulation Crowdfunding and Regulation D offering types. Reg CF offerings are provided by Bioverge Portal LLC and Reg D offering are provided by Bioverge Funds Management LLC. Companies designated as BV Showcase are enrolled in a program managed by Bioverge Inc and are not associated with an offering on the Bioverge platform.
